Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
Open accessThe DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
Is cancer immunotherapy a private affair?: Immune checkpoint blockade, a relatively new cancer treatment, substantially extends the survival of a subset of patients. Previous work has shown that patients whose tumors harbor the largest number of mutations—and thus produce a large number of “neoantigens” recognized as foreign by the immune system—are most likely to benefit. Expanding on these earlier studies, Van Allen et al. studied over 100 patients with melanoma and found a similar correlation (see the Perspective by Gubin and Schreiber). There was no evidence, however, that specific neoantigen sequences were shared by patients who responded. Science , this issue p. 207 , see also p. 158
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“ORR and Kaplan-Meier survival analysis revealed that the PathTIGR model effectively stratified patients with melanoma into subgroups exhibiting significantly disparate therapeutic responses (Fisher’s exact test, P < 0.0001; Fig. 4C) and clinical outcomes (log-rank test, P < 0.0001; Fig. 4, D and E).”
From PathTIGR: A pathway topology-informed graph representation learning framework for immunotherapy response prediction (2026) · doi:10.1126/sciadv.aed6373 · cites this paper as [37]
In the citing paper
“ORR and Kaplan-Meier survival analysis revealed that the PathTIGR model effectively stratified patients with melanoma into subgroups exhibiting significantly disparate therapeutic responses (Fisher’s exact test, P < 0.0001; Fig. 4C) and clinical outcomes (log-rank test, P < 0.0001; Fig. 4, D and E).”
From PathTIGR: A pathway topology-informed graph representation learning framework for immunotherapy response prediction (2026) · doi:10.1126/sciadv.aed6373 · cites this paper as [37]
In the citing paper
“The model achieved AUCs of 0.734, 0.729, and 0.935 at 1, 2, and 3 years, respectively (Fig. 4F).”
From PathTIGR: A pathway topology-informed graph representation learning framework for immunotherapy response prediction (2026) · doi:10.1126/sciadv.aed6373 · cites this paper as [37]
In the citing paper
“Cox proportional hazard regression analysis established the algorithm’s independence as a prognostic determinant following adjustment for conventional clinicopathological covariates (P < 0.001; Fig. 4G and table S1).”
From PathTIGR: A pathway topology-informed graph representation learning framework for immunotherapy response prediction (2026) · doi:10.1126/sciadv.aed6373 · cites this paper as [37]
In the citing paper
“it achieved an AUC of 0.989, an AUPRC of 0.993, an F1 score of 0.99, and a C-index of 0.989 (Fig. 4, A and B, and fig. S2A).”
From PathTIGR: A pathway topology-informed graph representation learning framework for immunotherapy response prediction (2026) · doi:10.1126/sciadv.aed6373 · cites this paper as [37]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534 · cited 2×
“To stratify our cohort, “clinical benefit” was defined using a composite end point of complete response or partial response to ipilimumab by RECIST criteria (21) or stable disease by RECIST criteria with overall survival greater than 1 year (n = 27).”
Robinson, J. T., Thorvaldsdóttir, H., Winckler, W., Guttman, M., Lander, E. S., Getz, G., & Mesirov, J. P. (2011) · Nature Biotechnology · doi:10.1038/nbt.1754 · Cited by 15,390
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citationPD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Self-citationMutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples
Cibulskis, K., Lawrence, M. S., Carter, S. L., Sivachenko, A., Jaffe, D., Sougnez, C., Gabriel, S., Meyerson, M., Lander, E. S., & Getz, G. (2013) · Nature Biotechnology · doi:10.1038/nbt.2514 · Cited by 4,981 · cited 1×
“We performed somatic mutation identification (table S1) and germline human lymphocyte antigen (HLA) typing (table S2) using established methods (14, 19).”
Self-citationThe future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878 · cited 1×
“Incorporation of patient-matched RNA-level information may help prioritize putative neoantigens and elucidate possible tumor immune microenvironmental effects, including interferon-related genes and additional immune checkpoint molecules that are relevant in melanoma (28).”
Cited by
Items 801–900 of 1,010
Mullane, S. A., Werner, L., Rosenberg, J., Signoretti, S., Callea, M., Choueiri, T. K., Freeman, G. J., & Bellmunt, J. (2016) · Scientific Reports · doi:10.1038/srep27702 · Cited by 55
Biomarkers for immune therapy in colorectal cancer: mismatch-repair deficiency and others
Bupathi, M., & Wu, C. S.-Y. (2016) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2016.07.03 · Cited by 61
“evaluated tumor biopsies of patients with metastatic melanoma before and after anticytotoxic T lymphocyte-associated protein 4 (anti-CTLA-4) immunotherapy (50).”
BackgroundSelf-citationBudczies, J., Mechtersheimer, G., Denkert, C., Klauschen, F., Mughal, S. S., Chudasama, P., Bockmayr, M., Jöhrens, K., Endris, V., Lier, A., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1279777 · Cited by 55
Comprehensive immunoproteogenomic analyses of malignant pleural mesothelioma
Lee, H.-S., Jang, H.-J., Choi, J. M., Zhang, J., de Rosen, V. L., Wheeler, T. M., Lee, J.-S., Tu, T., Jindra, P. T., Kerman, R. H., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.98575 · Cited by 55
The Immune Contexture Associates with the Genomic Landscape in Lung Adenomatous Premalignancy
Krysan, K., Tran, L. M., Grimes, B. S., Fishbein, G. A., Seki, A., Gardner, B. K., Walser, T. C., Salehi‐Rad, R., Yanagawa, J., Lee, J. M., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-0153 · Cited by 61
“Consistent with findings in melanoma (40) and colorectal cancer (41), our analysis of mutations in lung adenocarcinoma indicates that while there are many commondrivermutations among tumors fromdifferent patients, mutations producing PANs are most often unique to individual patients.”
ResultKoumantou, D., Barnea, E., Martín‐Esteban, A., Maben, Z., Papakyriakou, A., Mpakali, A., Kokkala, P., Pratsinis, H., Georgiadis, D., Stern, L. J., et al. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02358-0 · Cited by 55
Imperial, R. J. L., Nazer, M., Ahmed, Z., Kam, A. E., Pluard, T., Bahaj, W., Levy, M. A., Kuzel, T. M., Hayden, D. M., Pappas, S. G., et al. (2019) · Cancers · doi:10.3390/cancers11091399 · Cited by 56
Modulation of the immune microenvironment by tumor-intrinsic oncogenic signaling
Nguyen, K. B., & Spranger, S. (2019) · The Journal of Cell Biology · doi:10.1083/jcb.201908224 · Cited by 58
Screening Cancer Immunotherapy: When Engineering Approaches Meet Artificial Intelligence
Zhou, X., Qu, M., Tebon, P. J., Jiang, X., Wang, C., Xue, Y., Zhu, J., Zhang, S., Öklü, R., Sengupta, S., et al. (2020) · Advanced Science · doi:10.1002/advs.202001447 · Cited by 60
EPHA7 mutation as a predictive biomarker for immune checkpoint inhibitors in multiple cancers
Zhang, Z., Wu, H., Lin, W., Wang, Z., Yang, L.-P., Zeng, Z.-L., & Luo, H. (2021) · BMC Medicine · doi:10.1186/s12916-020-01899-x · Cited by 63
Novel Combination Therapies for the Treatment of Bladder Cancer
Peng, M., Xiao, D., Bu, Y., Long, J., Yang, X. F., Lv, S., & Yang, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.539527 · Cited by 56
“Studies also reported that defects in DNA damage repair (DDR) genes could be potential predictive biomarkers of clinical response to ICIs in metastatic urothelial bladder cancer (46, 47).”
BackgroundTumor-Infiltrating Lymphocytes and Their Role in Solid Tumor Progression
Whiteside, T. L. (2022) · Experientia supplementum · doi:10.1007/978-3-030-91311-3_3 · Cited by 70
Widespread hypertranscription in aggressive human cancers
Zatzman, M., Fuligni, F., Ripsman, R., Suwal, T., Comitani, F., Edward, L.-M., Denroche, R. E., Jang, G. H., Notta, F., Gallinger, S., et al. (2022) · Science Advances · doi:10.1126/sciadv.abn0238 · Cited by 71
Surface Oncology, 5. H. S., Rausch, M. P., & Hastings, K. T. (2017) · Codon Publications eBooks · doi:10.15586/codon.cutaneousmelanoma.2017.ch9 · Cited by 73
“Similarly, neoantigen load was shown to correlate with clinical response in a second cohort of melanoma patients treated with ipilimumab (70).”
BackgroundNivolumab Plus Ipilimumab in Non-Small-Cell Lung Cancer
Reck, M., Borghaei, H., & O'Byrne, K. J. (2019) · Future Oncology · doi:10.2217/fon-2019-0031 · Cited by 58
Chang, H., Sasson, A., Srinivasan, S., Golhar, R., Greenawalt, D. M., Geese, W. J., Green, G., Zerba, K., Kirov, S., & Szustakowski, J. (2019) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-019-00408-y · Cited by 54
Beyond Tumor PD-L1: Emerging Genomic Biomarkers for Checkpoint Inhibitor Immunotherapy
Lagos, G., Izar, B., & Rizvi, N. A. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_289967 · Cited by 61
Emerging Strategies in TCR-Engineered T Cells
Fang, W., Cheng, X., Xue, J. Z., & Xue, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.850358 · Cited by 65
“Indeed, evidence from treatment of cancers with checkpoint blockade suggests that tumors with higher mutational burden are likely to respond to immunotherapy (251, 252).”
BackgroundTumour neoantigen mimicry by microbial species in cancer immunotherapy
Boesch, M., Baty, F., Rothschild, S. I., Tamm, M., Joerger, M., Früh, M., & Brutsche, M. H. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01365-2 · Cited by 58
Ke, M., Xu, T., Fang, Y., Ye, Y., Li, Z.-J., Ren, F., Lu, S., Zhang, X., Wu, R., Lv, Y., et al. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.05.007 · Cited by 54
Late-Stage Metastatic Melanoma Emerges through a Diversity of Evolutionary Pathways
Spain, L. A., Coulton, A., Lobón, I., Rowan, A., Schnidrig, D., Shepherd, S. T. C., Shum, B., Byrne, F., Goicoechea, M., Piperni, E., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-1427 · Cited by 63
Zhang, P., Zhang, X., Cui, Y., Gong, Z., Wang, W. T., & Lin, S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1244144 · Cited by 57
“A comparison of IPS was carried out between the high-risk and low-risk groups in this study (34).”
BackgroundMetastatic melanoma and immunotherapy
Herzberg, B., & Fisher, D. E. (2016) · Clinical Immunology · doi:10.1016/j.clim.2016.07.006 · Cited by 60
“Indeed, mutation burden alone has been correlated with the response of melanoma to ipilimumab [81-83].”
BackgroundWalsh, K. B., Zhang, X., Zhu, X., Wohleb, E., Woo, D., Lu, L. J., & Adeoye, O. M. (2019) · DNA and Cell Biology · doi:10.1089/dna.2018.4550 · Cited by 56
“Findings from RNAseq have shown increasing promise for the study of disease and clinical management (Deng et al., 2006; Coates et al., 2015; Van Allen et al., 2015; Byron et al., 2016).”
BackgroundEder, T., Hess, A. K., Konschak, R., Stromberger, C., Jöhrens, K., Fleischer, V., Hummel, M., Balermpas, P., von der Grün, J., Linge, A., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.04.015 · Cited by 67
Primary and acquired resistance mechanisms to immune checkpoint inhibition in Hodgkin lymphoma
Veldman, J., Visser, L., van den Berg, A., & Diepstra, A. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.101931 · Cited by 56
“Increased TMB has been associated with an improved response to immune checkpoint inhibition in several cancers [12,29].”
BackgroundZhou, Z., Zhang, J., Xu, C., Yang, J., Zhang, Y., Liu, M., Shi, X., Li, X., Zhan, H., Chen, W., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103271 · Cited by 57
“To evaluate the role of this m6Ascore model in predicting response to immunotherapy, we analyzed two independent cohorts of patients received ICIs treatment [33,34].”
BackgroundMethodCai, M., Zhao, X., Cao, M., Ma, P., Chen, M., Wu, J., Jia, C., He, C., Fu, Y., Tan, L., et al. (2020) · The Journal of Pathology · doi:10.1002/path.5435 · Cited by 58
Ji, P., Yang, Z., Li, H., Wei, M., Yang, G., Xing, H., & Li, Q. (2021) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2021.10.009 · Cited by 56
“Recently, checkpoint blockade therapies, such as anti-PD-1 and anti-CTLA-4,(38) showed success in promoting antitumor immune responses of certain cancers.(39,40) Chimeric antigen receptor T cell immunotherapy is another promising strategy for tumor immunotherapy,(41) although identification of cancer-specific antigens…”
BackgroundConroy, J. M., Pabla, S., Glenn, S. T., Seager, R. J., Roey, E. V., Gao, S., Burgher, B., Andreas, J., Giamo, V., Mallon, M., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0260089 · Cited by 54
Anagnostou, V., Landon, B. V., Medina, J. E., Forde, P. M., & Velculescu, V. E. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abo3958 · Cited by 54
“Although several machine learning approaches have been developed to computationally deriveMHC class I– and II–restricted neopeptides from next-generation sequencing data, these efforts have largely yielded similar prediction accuracy for computationally identified MANA load compared to TMB (27, 37, 51, 52).”
ResultZhang, P., Zhang, H., Tang, J., Ren, Q., Zhang, J., Chi, H., Xiong, J., Gong, X., Wang, W. T., Lin, H., et al. (2023) · Aging · doi:10.18632/aging.205077 · Cited by 58
“Leveraging the potential to predict the responsiveness to immunotherapeutic interventions, the Cancer Immunome Atlas (TCIA) database was harnessed, serving as a repository to access the Immunophenoscores (IPS) data specific to the TCGA-LUAD population [40].”
MethodChand, D. S., Savitsky, D. A., Krishnan, S., Mednick, G., Delepine, C., García‐Broncano, P., Soh, K. T., Wu, W., Wilkens, M. K., Udartseva, O. O., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0190 · Cited by 63
“…predictive biomarkers of human α CTLA-4 response are emerging, botensilimab response seems independent of known response signatures for ipilimumab alone or ipilimumab plus α PD-1, including tumor neoantigen burden (55), FCGR3A allele status (15), and intratumoral CD8 + T-cell infiltration (59).”
Ye, B., Jiang, A., Feng, L., Wang, C., Liang, X., & Zhang, P. (2024) · BioFactors · doi:10.1002/biof.2142 · Cited by 58
Kardos, J., Wobker, S. E., Woods, M. E., Nielsen, M. E., Smith, A., Wallen, E., Pruthi, R. S., Hayward, M. C., McGinty, K., Grilley‐Olson, J. E., et al. (2017) · JCO Precision Oncology · doi:10.1200/po.17.00027 · Cited by 54
Checkpoint immunotherapy in head and neck cancers
Zolkind, P., & Uppaluri, R. (2017) · Cancer and Metastasis Reviews · doi:10.1007/s10555-017-9694-9 · Cited by 51
Acquired resistance to cancer immunotherapy
Draghi, A., Chamberlain, C. A., Furness, A. J. S., & Donia, M. (2018) · Seminars in Immunopathology · doi:10.1007/s00281-018-0692-y · Cited by 52
Tuccitto, A., Shahaj, E., Vergani, E., Ferro, S., Huber, V., Rodolfo, M., Castelli, C., Rivoltini, L., & Vallacchi, V. (2018) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-018-2477-z · Cited by 55
“Mutational load Melanoma and 27 tumor types ND CTLA-4, PD-1, PD-L1 Response Immune signatures in R [23, 24] Indel number Melanoma ND PD-1 Response ND [25] DNA MMR MMRD colorectal cancer ND PD-1 Response High CD8 and PD-L1 [26] BRCA2 Melanoma 28% PD-1 Response Immune signatures in R [27] TP53 Lung adenocarcinoma 33% PD…”
BackgroundRecent Advances in Polymeric Nanomedicines for Cancer Immunotherapy
Lee, E. S., Shin, J. M., Son, S., Ko, H., Um, W., Song, S. H., Lee, J. A., & Park, J. H. (2019) · Advanced Healthcare Materials · doi:10.1002/adhm.201801320 · Cited by 54
Obesity and the Impact on Cutaneous Melanoma: Friend or Foe?
Smith, L. K., Arabi, S., Lelliott, E. J., McArthur, G. A., & Sheppard, K. E. (2020) · Cancers · doi:10.3390/cancers12061583 · Cited by 64
Kobayashi, Y., Kushihara, Y., Saito, N., Yamaguchi, S., & Kakimi, K. (2020) · Cancer Science · doi:10.1111/cas.14621 · Cited by 60
He, Y., & Wang, X. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-922 · Cited by 57
“Recently, with the advance of immunotherapy in treating various advanced malignancies including the cancers with mismatch repair deficiency (3-7), immunotherapy is becoming a potentially promising treatment strategy for GC, as evidenced by that pembrolizumab and nivolumab (immune checkpoint inhibitors) are being clini…”
Biomarkers for Response to Immune Checkpoint Blockade
Ganesan, S., & Mehnert, J. (2020) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030419-033604 · Cited by 51
“The gene expression profile (GEP) was then evaluated in a cohort of over 300 patients from 4 trials of single-agent pembrolizumab in 22 tumor types (enriched in melanoma and HNSCC), S ee c r i 2018).”
BackgroundMethodPark, S., Joung, J., Min, Y. W., Nam, J., Ryu, D., Oh, D., Park, W., Lee, S. K., Choi, Y., Ahn, J. S., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0609-x · Cited by 57
Gan, X., Shan, Q., Li, H., Janssens, R., Shen, Y., He, Y., Chen, F., van Haperen, R., Drabek, D., Li, J., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2200879119 · Cited by 56
Scheel, A. H., Dietel, M., Heukamp, L. C., Jöhrens, K., Kirchner, T., Reu, S., Rüschoff, J., Schildhaus, H., Schirmacher, P., Tiemann, M., et al. (2016) · Der Pathologe · doi:10.1007/s00292-016-0189-1 · Cited by 62
Comprehensive Outline of Whole Exome Sequencing Data Analysis Tools Available in Clinical Oncology
Bartha, Á., & Győrffy, B. (2019) · Cancers · doi:10.3390/cancers11111725 · Cited by 67
Identification and Utilization of Biomarkers to Predict Response to Immune Checkpoint Inhibitors
Gjoerup, O. V., Brown, C. A., Ross, J. S., Huang, R. S. P., Schrock, A. B., Creeden, J., Fabrizio, D. A., & Tolba, K. A. (2020) · The AAPS Journal · doi:10.1208/s12248-020-00514-4 · Cited by 55
Lin, X., Wang, L., Xie, X., Qin, Y., Xie, Z., Ouyang, M., & Zhou, C. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.602328 · Cited by 53
Precision Medicine and Melanoma: Multi-Omics Approaches to Monitoring the Immunotherapy Response
Valenti, F., Falcone, I., Ungania, S., Desiderio, F., Giacomini, P., Bazzichetto, C., Conciatori, F., Gallo, E., Cognetti, F., Ciliberto, G., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22083837 · Cited by 60
“In recent years, gene sequencing studies have shown that the TMB, neoantigen load (NL) or PDL1 expression degree are often associated with an increased response to immunotherapy [47,48].”
BackgroundCheckpoint blockade-induced CD8+ T cell differentiation in head and neck cancer responders
Zhou, L., Zeng, Z., Egloff, A. M., Zhang, F., Guo, F., Campbell, K. M., Du, P. P., Fu, J., Zolkind, P., Ma, X., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004034 · Cited by 50
Personalizing neoadjuvant immune-checkpoint inhibition in patients with melanoma
Lucas, M. W., Versluis, J. M., Rozeman, E. A., & Blank, C. U. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00760-3 · Cited by 50
Self-citationDyer, B. A., Feng, C. H., Eskander, R. N., Sharabi, A. B., Mell, L. K., McHale, M. T., & Mayadev, J. (2020) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2020.09.016 · Cited by 56
de Lima, V. A. B., Hansen, M., Spanggaard, I., Rohrberg, K. S., Hadrup, S. R., Lassen, U., & Svane, I. M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.558248 · Cited by 64
Ning, H., HUANG, S. H., Yang, L., Zhi, R., Yan, H., Jin, J., Hu, Z., Guo, K., Liu, J., Yang, J., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34253-1 · Cited by 58
Tumor Mutational Burden in Breast Cancer: Current Evidence, Challenges, and Opportunities
Barroso‐Sousa, R., Pacifico, J. P. M., Sammons, S. L., & Tolaney, S. M. (2023) · Cancers · doi:10.3390/cancers15153997 · Cited by 58
S100A9 and HMGB1 orchestrate MDSC-mediated immunosuppression in melanoma through TLR4 signaling
Kurt, F. G. Ö., Cicortas, B.-A., Balzasch, B. M., Torre, C. D. L., Ast, V., Tavukçuoğlu, E., Ak, C., Wohlfeil, S. A., Cerwenka, A., Utikal, J. S., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-009552 · Cited by 63
Self-citationGenomic Evolution after Chemoradiotherapy in Anal Squamous Cell Carcinoma
Mouw, K. W., Cleary, J. M., Reardon, B. M., Pike, J. W., Braunstein, L. Z., Kim, J., Amin‐Mansour, A., Miao, D., Damish, A. W., Chin, J., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2017 · Cited by 51
“Given that DNA damage-induced somatic mutations can result in novel cancerspecific neoantigens, we used patient-specific non-synonymous mutations and HLA types to predict putative immunogenic neoantigens for matched primary and recurrent tumors from the pilot cohort (Methods, Supplementary Information).[16] As expecte…”
MethodSelf-citationCancer stem cell immunology and immunotherapy: Harnessing the immune system against cancer's source
Ruiu, R., Tarone, L., Rolih, V., Barutello, G., Bolli, E., Riccardo, F., Cavallo, F., & Conti, L. (2019) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2019.03.008 · Cited by 52
The role of immune infiltrates as prognostic biomarkers in patients with breast cancer
Baxevanis, C. N., Sofopoulos, M., Fortis, S. P., & Perez, S. A. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02327-7 · Cited by 54
Identification of Neoantigen-Reactive Tumor-Infiltrating Lymphocytes in Primary Bladder Cancer
Leko, V., McDuffie, L. A., Zheng, Z., Gartner, J. J., Prickett, T. D., Apolo, A. B., Agarwal, P. K., Rosenberg, S. A., & Lu, Y.-C. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1801022 · Cited by 50
Tissue Site and the Cancer Immunity Cycle
Horton, B. L., Fessenden, T. B., & Spranger, S. (2019) · Trends in cancer · doi:10.1016/j.trecan.2019.07.006 · Cited by 59
The Resistance Mechanisms of Checkpoint Inhibitors in Solid Tumors
Koustas, E., Sarantis, P., Papavassiliou, A. G., & Karamouzis, M. V. (2020) · Biomolecules · doi:10.3390/biom10050666 · Cited by 57
Therapeutic nanovaccines sensitize EBV-associated tumors to checkpoint blockade therapy
Liu, H., Chen, H., Liu, Z., Le, Z., Nie, T., Qiao, D., Su, Y. A., Mai, H., Chen, Y., & Liu, L. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120158 · Cited by 50
Epidemiology, Risk Assessment, and Biomarkers for Patients with Advanced Renal Cell Carcinoma
Attalla, K., Weng, S., Voss, M. H., & Hakimi, A. A. (2020) · Urologic Clinics of North America · doi:10.1016/j.ucl.2020.04.002 · Cited by 51
Zhao, R., Li, B., Zhang, S., He, Z., Pan, Z., Li, X., Guo, Q., Qi, Y., Qi, Y., Zhao, S., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.653711 · Cited by 56
“org/), and the detailed clinical characteristics of individual patients were obtained from the supplementary data of a previous paper (23).”
BackgroundMethodInfluentialZhang, W., Shi, F., Kong, Y., Li, Y., Sheng, C., Wang, S., & Wang, Q. (2021) · Cancer Medicine · doi:10.1002/cam4.4472 · Cited by 59
Neoantigen-based personalized cancer vaccines: the emergence of precision cancer immunotherapy
Richard, G., Princiotta, M. F., Bridon, D. P., Martin, W. D., Steinberg, G. D., & Groot, A. S. D. (2021) · Expert Review of Vaccines · doi:10.1080/14760584.2022.2012456 · Cited by 53
“non-small cell lung cancer (NSCLC) patients treated with pembrolizumab [16] and of metastatic melanoma patients treated with ipilimumab [17].”
BackgroundIntratumor Heterogeneity and Antitumor Immunity Shape One Another Bidirectionally
Wolf, Y., & Samuels, Y. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1355 · Cited by 53
“Observations of an initial association between responsiveness to ICB and tumor mutational burden (TMB), especially in tumors with a high TMB — i.e., in melanoma (6, 7), non – small cell lung cancer (NSCLC; ref.”
BackgroundMao, Y., Xie, H., Lv, M., Yang, Q., Shuang, Z., Gao, F., Li, S., Zhu, L., & Wang, W. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03441-3 · Cited by 61
An Expanding Role for Immunotherapy in Colorectal Cancer
Bever, K. M., & Le, D. T. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0037 · Cited by 51
The Potential of Donor T-Cell Repertoires in Neoantigen-Targeted Cancer Immunotherapy
Karpanen, T., & Olweus, J. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01718 · Cited by 49
Cytosolic Iron-Sulfur Assembly Is Evolutionarily Tuned by a Cancer-Amplified Ubiquitin Ligase
Weon, J. L., Yang, S. W., & Potts, P. R. (2017) · Molecular Cell · doi:10.1016/j.molcel.2017.11.010 · Cited by 52
“Several studies have attributed these differences to the abundance of neoantigens presented to the competent immune cells after delivery of checkpoint inhibitors (Rizvi et al., 2015; Van Allen et al., 2015).”
Genomics-Guided Immunotherapy for Precision Medicine in Cancer
Mukherjee, S. (2019) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2018.2758 · Cited by 57
“This study also obtained transcriptome data and found that high expression of granzyme A (GZMA) and perforin (PRF1), improves response to checkpoint inhibitor-based immunotherapy.(64) The cancer microenvironment consists of different types of 490 MUKHERJEE”
BackgroundTumour mutational burden: primary versus metastatic tissue creates systematic bias
Schnidrig, D., Turajlic, S., & Litchfield, K. (2019) · Immuno-Oncology Technology · doi:10.1016/j.iotech.2019.11.003 · Cited by 55
Jiang, A., Ren, M., Liu, N., Gao, H., Wang, J.-J., Zheng, X., Fu, X., Liang, X., Ruan, Z., Tian, T., et al. (2020) · International Journal of Medical Sciences · doi:10.7150/ijms.51064 · Cited by 59
“In recent years, the clinical application of immune checkpoint inhibitors (ICIs) has demonstrated promising response rates in various malignant tumors, approving that it could play an antitumor role by reversing immunodeficiency and activating the immune cells [5-10].”
BackgroundZhang, P., Kitchen-Smith, I., Xiong, L., Stracquadanio, G., Brown, K., Richter, P., Wallace, M. D., Bond, E. E., Sahgal, N., Moore, S., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-0177 · Cited by 48
“6E), for which both the somatic genetic and expression data are available (47).”
BackgroundLorenzo, S. D., Tovoli, F., & Trevisani, F. (2022) · Cancers · doi:10.3390/cancers14194616 · Cited by 59
Immune-checkpoint inhibitors in non-small cell lung cancer: A tool to improve patients’ selection
Banna, G. L., Passiglia, F., Colonese, F., Canova, S., Menis, J., Addeo, A., Russo, A. D., & Cortinovis, D. L. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.06.016 · Cited by 50
Guo, X.-J., Lu, J., Zeng, H., Zhou, R., Sun, Q., Yang, G., Pei, Y.-Z., Meng, X., Shen, Y., Zhang, P., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.705378 · Cited by 53
“Therefore, CTLA-4 acts as a central element of immunologic tolerance to lessen the immune response in the tumor microenvironment (38).”
BackgroundYan, M., Hu, J., Ping, Y., Xu, L., Liao, G., Jiang, Z., Pang, B., Sun, S., Zhang, Y., Xiao, Y., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.758288 · Cited by 52
Fucikova, J. P., Hensler, M., Kašíková, L., Láníčková, T., Pasulka, J., Raková, J., Drozenová, J., Fredriksen, T., Hraska, M., Hrnčiarová, T., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-4413 · Cited by 58
Zhang, W., Zhu, Y., Liu, H., Zhang, Y., Liu, H., Adegboro, A. A., Dang, R., Dai, L., Wanggou, S., & Li, X. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00570-5 · Cited by 53
Precision medicine driven by cancer systems biology
Filipp, F. V. (2017) · Cancer and Metastasis Reviews · doi:10.1007/s10555-017-9662-4 · Cited by 59
Tumor-Infiltrating Lymphocyte Therapy and Neoantigens
Robbins, P. F. (2017) · The Cancer Journal · doi:10.1097/ppo.0000000000000267 · Cited by 54
Theodoraki, M., Lorenz, K. J., Lotfi, R., Furst, D. E., Tsamadou, C., Jäkle, S. S., Mytilineos, J., Brunner, C., Theodorakis, J., Hoffmann, T. K., et al. (2017) · Photodiagnosis and Photodynamic Therapy · doi:10.1016/j.pdpdt.2017.05.015 · Cited by 52
Lu, T., Wang, S., Xu, L., Zhou, Q., Singla, N., Gao, J., Manna, S., Pop, L., Xie, Z., Chen, M., et al. (2020) · Science Immunology · doi:10.1126/sciimmunol.aaz3199 · Cited by 48
ASNEO: Identification of personalized alternative splicing based neoantigens with RNA-seq
Zhang, Z., Zhou, C., Tang, L., Gong, Y., Wei, Z., Zhang, G., Wang, F., Liu, Q., & Yu, J. (2020) · Aging · doi:10.18632/aging.103516 · Cited by 52
“consistent with previous study [15], but AS neoantigen burden was not associated with the response (Wilcoxon test, P=0.”
BackgroundMethodResultProgress in Neoantigen Targeted Cancer Immunotherapies
Han, X.-J., Ma, X.-L., Yang, L., Wei, Y.-Q., Peng, Y., & Wei, X.-W. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00728 · Cited by 47
“…et al., 2015; Rizvi et al., 2015; Andor and Graham, 2016; "Erratum for the Report "Genomic correlates of response to CTLA-4 blockade in metastatic melanoma" by Van Allen et al., 2016; Hugo et al., 2016; Matsushita et al., 2016; McGranahan et al., 2016; Morris et al., 2016; Rosenberg et al., 2016).”
BackgroundThe immunology of low-grade gliomas
Haddad, A. F., Young, J. S., Oh, J. Y., Okada, H., & Aghi, M. K. (2022) · Neurosurgical FOCUS · doi:10.3171/2021.11.focus21587 · Cited by 49
Hong, M. M. Y., & Vareki, S. M. (2022) · Cancers · doi:10.3390/cancers14061580 · Cited by 54
“The efficacy of anti-CTLA-4 is therefore dependent on the accessibility and array of neoantigens [128,129].”
BackgroundIntegrated genomic analyses of acral and mucosal melanomas nominate novel driver genes
Wang, M., Banik, I., Shain, A. H., Yeh, I., & Bastian, B. C. (2022) · Genome Medicine · doi:10.1186/s13073-022-01068-0 · Cited by 50
Understanding the tumor microenvironment in head and neck squamous cell carcinoma
Sadeghirad, H., Shiravand, Y., Radfar, P., Ladwa, R., Perry, C., Han, X., Warkiani, M. E., Adams, M. N., Hughes, B. G. M., O'Byrne, K. J., et al. (2022) · Clinical & Translational Immunology · doi:10.1002/cti2.1397 · Cited by 57
Hak, C. C. W., Rullan, A., Patin, E. C., Pedersen, M., Melcher, A. A., & Harrington, K. J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.971959 · Cited by 51
Javitt, A., Shmueli, M. D., Kramer, M. P., Kolodziejczyk, A. A., Cohen, I., Radomir, L., Sheban, D., Kamer, I., Litchfield, K., Bab-Dinitz, E., et al. (2023) · Nature Cancer · doi:10.1038/s43018-023-00557-4 · Cited by 59
Tumor monocyte content predicts immunochemotherapy outcomes in esophageal adenocarcinoma
Carroll, T. M., Chadwick, J. A., Owen, R. P., White, M. J., Kaplinsky, J., Peneva, I., Frangou, A., Xie, P. F., Chang, J., Roth, A. J. L., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.06.006 · Cited by 60
Sehgal, K., Παππά, Θ., Shin, K., Schiantarelli, J., Liu, M., Ricker, C. A., Besson, N. R., Jones, S. M., Welsh, E. L., Pfaff, K. L., et al. (2024) · JAMA Oncology · doi:10.1001/jamaoncol.2024.4019 · Cited by 58
Immunotherapy in human colorectal cancer: Challenges and prospective
Sun, X., Suo, J., & Yan, J. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i28.6362 · Cited by 52
Biomarkers and Immunotherapeutic Targets in Glioblastoma
Hung, A. L., Garzón-Muvdi, T., & Lim, M. K. (2017) · World Neurosurgery · doi:10.1016/j.wneu.2017.03.011 · Cited by 53
Clinical Features of Acquired Resistance to Anti–PD-1 Therapy in Advanced Melanoma
Wang, D. Y., Eroglu, Z., Özgün, A., Leger, P. D., Zhao, S., Ye, F., Luke, J. J., Joseph, R. W., Haq, R., Ott, P. A., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0287 · Cited by 52
Metadata
- Authors
- Van Allen, E. M., Miao, D., Schilling, B., Shukla, S. A., Blank, C., Zimmer, L., Sucker, A., Hillen, U., Geukes Foppen, M. H., Goldinger, S. M., Utikal, J., Hassel, J. C., Weide, B., Kaehler, K. C., Loquai, C., Mohr, P., Gutzmer, R., Dummer, R., Gabriel, S., Wu, C. J., Schadendorf, D., & Garraway, L. A.
- Affiliations
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
- Broad Institute (US)
- Deutsches Konsortium für Translationale Krebsforschung (DE)
- The Netherlands Cancer Institute (NL)
- Department of Medical Oncology, Netherlands Cancer Institute, 1066 CX Amsterdam, Netherlands.
- University Hospital Zurich (CH)
- German Cancer Research Center (DE)
- Heidelberg University (DE)
- Universitätsklinikum Tübingen (DE)
- University Hospital Schleswig-Holstein (DE)
- University Medical Center of the Johannes Gutenberg University Mainz (DE)
- Elbe Kliniken Stade-Buxtehude (DE)
- Medizinische Hochschule Hannover (DE)
- Corresponding author
- Miao, Diana
- Schilling, Bastian
- Schadendorf, Dirk
- Garraway, Levi A.
- ORCID
- Venue
- Science
- Published
- 2015-10-09
- Volume
- 350
- Issue
- 6257
- Pages
- 207-211
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC5054517
- OpenAlex
- W2107429737
- Cited by
- 2,839
- References
- 42
- Citations by year
- 2026: 106 · 2025: 187 · 2024: 236 · 2023: 308 · 2022: 313 · 2021: 348 · 2020: 327 · 2019: 274 · 2018: 270 · 2017: 248 · 2016: 207 · 2015: 12
- FWCI
- 107.45
- Type
- journal article
- Language
- en
- Update notices
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion)
- Funders
- NIH (U54 HG003067)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- metastatic melanoma, CTLA-4 blockade, ipilimumab, immune checkpoint inhibitors, tumor mutational burden, neoantigens, tumor microenvironment, predictive biomarkers, treatment response, exome sequencing, transcriptome, germline mutations
- MeSH terms
- Ipilimumab, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antigens, Neoplasm, DNA Mutational Analysis, Female, HLA Antigens, Humans, Male, Melanoma, Middle Aged, Mutation, Skin Neoplasms, Cohort Studies, Drug Resistance, Neoplasm, Genomics, Biomarkers, Pharmacological, Young Adult, Tumor Microenvironment, Cell Cycle Checkpoints, Exome, CTLA-4 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.